Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
The company plans to add 1700 beds by FY27 through the organic route
TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery
This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
Subscribe To Our Newsletter & Stay Updated
